Why the study?
Do PAF antagonists reduce arrhythmias and platelet activation in a greyhound model of acute myocardial ischaemia and reperfusion?
Do PAF antagonists reduce arrhythmias and platelet activation in a greyhound model of acute myocardial ischaemia and reperfusion?
PAF antagonists attenuate ischemia and reperfusion-induced arrhythmias and platelet activation in an experimental greyhound model, suggesting a role for PAF in these processes.
Answers are grounded in this paper and cite their sources.
Does not change clinical practice; leaves open a role for PAF in human ischemia-reperfusion arrhythmias.
The aim of the study was to examine a possible role for platelet activating factor (PAF) in experimental myocardial ischaemia and reperfusion. Anaesthetized open-chest greyhounds were subjected to 40 min of coronary artery (LAD) occlusion followed by reperfusion. Blood samples for platelet counting were obtained from a local coronary vein draining the ischaemic region. Pretreatment with PAF antagonists BN52021 (5 mg kg-1 i.v.) or SRI63441 (10 mg kg-1 i.v.), 15 min prior to occlusion reduced the ventricular ectopic count during the ischaemic period from 614 +/- 82 (controls) to 296 +/- 145 (BN52021) and 474 +/- 200 (SRI63441). Both drugs also reduced the incidence of ventricular fibrillation (VF) (during ischaemia and reperfusion) from 90% (controls), to 50% (BN52021) and 43% (SRI63441). Ischaemia was accompanied by a 32 +/- 7% reduction in coronary venous platelets; this was attenuated by both BN52021 (-2 +/- 6%) and SRI63441) (-1 +/- 5%). These results suggest that PAF may contribute to ischaemia and reperfusion-induced arrhythmias by activating platelets.
No takes yet. Share an insight, caveat, or question.
Wainwright et al. (1989) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: